Ignite Creation Date:
2024-05-06 @ 2:59 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04482153
Status:
UNKNOWN
Last Update Posted:
2020-07-22
First Post:
2020-07-16
Brief Title:
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals
Status:
UNKNOWN
Status Verified Date:
2020-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of our study is
1 The early detection of NAFLD in CKD patients with different stages stage I to IV to avoid progression to liver fibrosis
2 Evaluation of the relationship between the severity of fatty liver in NAFLD assessed by liver enzymes biochemical markers ultrasonography and grades of Fibroscan with CKD staging eGFR and proteinuria
1 The early detection of NAFLD in CKD patients with different stages stage I to IV to avoid progression to liver fibrosis
2 Evaluation of the relationship between the severity of fatty liver in NAFLD assessed by liver enzymes biochemical markers ultrasonography and grades of Fibroscan with CKD staging eGFR and proteinuria
Detailed Description:
Chronic kidney disease CKD is defined as presence of reduced glomerular filtration rate GFR 60 mlmin 173 m2 andor evidence of kidney damage usually indicated by albuminuria or proteinuria for 3 months or more irrespective of cause CKD stages are classified according to the National Kidney Foundation in to five stages according to estimated GFR
The prevalence of CKD is continuously rising in concert with the rising epidemic of its risk factors including ageing diabetes obesity metabolic syndrome smoking and hypertension
Non-alcoholic fatty liver disease NAFLD is one of the most common chronic liver diseases in Western countries It encompasses a spectrum of conditions with lipid deposition in hepatocytes ranging from simple steatosis to non-alcoholic steatohepatitis NASH
It is defined as fatty liver with inflammation and hepatocelullar injury with or without fibrosis advanced fibrosis and cirrhosis Metabolic syndrome with its clinical traits is highly prevalent in patients with NAFLD
Preliminary data suggest an association between CKD and NAFLD reported that the prevalence of CKD was significantly higher in patients with NASH compared to patients without NASH
Moreover Yassui k documented the presence of moderately decreased eGFR and high frequency of micro-albuminuria in patients with biopsy proven NASH
The diagnosis of NAFLDNASH is based on the gold standard of liver biopsy or less reliably on serum liver enzymes or ultrasound imaging However liver biopsy has its limitations apart from being an invasive procedure connected with serious complications
Many non-invasive procedures have been intensively applied to detect hepatic steatosis and fibrosis The Controlled Attenuation Parameter CAP can using transient elastography TE Fibroscan permits to efficiently separate different grades of severity of steatosis CAP is based on the properties of ultrasonic signals acquired by the Fibroscan It allows to simultaneously measure liver stiffness and CAP in the same liver volume
The volume used for the measurement by the Fibroscan is 200 times larger than that of a liver biopsy specimen Therefore the Fibroscan is used more and more in clinical practice
Many biochemical markers can be used for diagnosis of NAFLD such as tissue inhibitor of metalloproteinase 1 TIMP1 aminoterminal peptide of procollagen III P3NP
Up till now the relationship between NAFLD and CKD is still poorly understood and under discussed
The prevalence of CKD is continuously rising in concert with the rising epidemic of its risk factors including ageing diabetes obesity metabolic syndrome smoking and hypertension
Non-alcoholic fatty liver disease NAFLD is one of the most common chronic liver diseases in Western countries It encompasses a spectrum of conditions with lipid deposition in hepatocytes ranging from simple steatosis to non-alcoholic steatohepatitis NASH
It is defined as fatty liver with inflammation and hepatocelullar injury with or without fibrosis advanced fibrosis and cirrhosis Metabolic syndrome with its clinical traits is highly prevalent in patients with NAFLD
Preliminary data suggest an association between CKD and NAFLD reported that the prevalence of CKD was significantly higher in patients with NASH compared to patients without NASH
Moreover Yassui k documented the presence of moderately decreased eGFR and high frequency of micro-albuminuria in patients with biopsy proven NASH
The diagnosis of NAFLDNASH is based on the gold standard of liver biopsy or less reliably on serum liver enzymes or ultrasound imaging However liver biopsy has its limitations apart from being an invasive procedure connected with serious complications
Many non-invasive procedures have been intensively applied to detect hepatic steatosis and fibrosis The Controlled Attenuation Parameter CAP can using transient elastography TE Fibroscan permits to efficiently separate different grades of severity of steatosis CAP is based on the properties of ultrasonic signals acquired by the Fibroscan It allows to simultaneously measure liver stiffness and CAP in the same liver volume
The volume used for the measurement by the Fibroscan is 200 times larger than that of a liver biopsy specimen Therefore the Fibroscan is used more and more in clinical practice
Many biochemical markers can be used for diagnosis of NAFLD such as tissue inhibitor of metalloproteinase 1 TIMP1 aminoterminal peptide of procollagen III P3NP
Up till now the relationship between NAFLD and CKD is still poorly understood and under discussed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None